These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 13432466)

  • 21. Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time!
    Chalasani N
    Gastroenterology; 2009 Sep; 137(3):772-5. PubMed ID: 19638269
    [No Abstract]   [Full Text] [Related]  

  • 22. [Aureomycin and lichen ruber planus; report on 4 cases treated with aureomycin].
    ZAVARINI G; RUBBINI C
    Arcisp S Anna Ferrara; 1955; 8(1):55-60. PubMed ID: 14389115
    [No Abstract]   [Full Text] [Related]  

  • 23. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Some novel insights into the pathogenesis of alcoholic steatosis.
    Lakshman MR
    Alcohol; 2004 Aug; 34(1):45-8. PubMed ID: 15670665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conjugated linoleic acid does not reduce body fat but decreases hepatic steatosis in adult Wistar rats.
    Purushotham A; Shrode GE; Wendel AA; Liu LF; Belury MA
    J Nutr Biochem; 2007 Oct; 18(10):676-84. PubMed ID: 17368879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver.
    Larosche I; Lettéron P; Fromenty B; Vadrot N; Abbey-Toby A; Feldmann G; Pessayre D; Mansouri A
    J Pharmacol Exp Ther; 2007 May; 321(2):526-35. PubMed ID: 17277197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blood oxidative stress markers are unreliable markers of hepatic steatosis.
    Bonnefont-Rousselot D; Ratziu V; Giral P; Charlotte F; Beucler I; Poynard T;
    Aliment Pharmacol Ther; 2006 Jan; 23(1):91-8. PubMed ID: 16393285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oxidative stress and depletion of hepatic long-chain polyunsaturated fatty acids may contribute to nonalcoholic fatty liver disease.
    Videla LA; Rodrigo R; Araya J; Poniachik J
    Free Radic Biol Med; 2004 Nov; 37(9):1499-507. PubMed ID: 15454290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy.
    Mennesson N; Dumortier J; Hervieu V; Milot L; Guillaud O; Scoazec JY; Pilleul F
    J Comput Assist Tomogr; 2009; 33(5):672-7. PubMed ID: 19820490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard.
    El-Badry AM; Breitenstein S; Jochum W; Washington K; Paradis V; Rubbia-Brandt L; Puhan MA; Slankamenac K; Graf R; Clavien PA
    Ann Surg; 2009 Nov; 250(5):691-7. PubMed ID: 19806055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
    Verna EC; Berk PD
    Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incretin mimetics as a novel therapeutic option for hepatic steatosis.
    Tushuizen ME; Bunck MC; Pouwels PJ; van Waesberghe JH; Diamant M; Heine RJ
    Liver Int; 2006 Oct; 26(8):1015-7. PubMed ID: 16953843
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population?
    Hałoń A; Patrzałek D; Rabczyński J
    Transplant Proc; 2006; 38(1):193-5. PubMed ID: 16504700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-invasive quantification of hepatic fat fraction by fast 1.0, 1.5 and 3.0 T MR imaging.
    Schuchmann S; Weigel C; Albrecht L; Kirsch M; Lemke A; Lorenz G; Warzok R; Hosten N
    Eur J Radiol; 2007 Jun; 62(3):416-22. PubMed ID: 17267159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of ChREBP in hepatic steatosis and insulin resistance.
    Denechaud PD; Dentin R; Girard J; Postic C
    FEBS Lett; 2008 Jan; 582(1):68-73. PubMed ID: 17716660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of nitric oxide in the modulation of hepatic microcirculation and tissue oxygenation in an experimental model of hepatic steatosis.
    Ijaz S; Yang W; Winslet MC; Seifalian AM
    Microvasc Res; 2005 Nov; 70(3):129-36. PubMed ID: 16203017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A human hepatocellular in vitro model to investigate steatosis.
    Gómez-Lechón MJ; Donato MT; Martínez-Romero A; Jiménez N; Castell JV; O'Connor JE
    Chem Biol Interact; 2007 Jan; 165(2):106-16. PubMed ID: 17188672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
    Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
    Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of the lipogenic pathway in the development of hepatic steatosis.
    Postic C; Girard J
    Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
    Dentin R; Benhamed F; Hainault I; Fauveau V; Foufelle F; Dyck JR; Girard J; Postic C
    Diabetes; 2006 Aug; 55(8):2159-70. PubMed ID: 16873678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.